Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination

Journal of Virology

Volumn 83, Issue 9, 2009, Pages 4489-4497

  Fu, Shi Quan ^a   Yoo, Dae Goon ^a   Song, Jae Min ^a   Clements, John D ^b   Compans, Richard W ^a   Kang, Sang Moo ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN B SUBUNIT; CYTOKINE; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; KINETICS; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROVOCATION TEST; VIRUS LIKE AGENT;

ANIMALS; CELL LINE; DOGS; FEMALE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; KINETICS; MICE; MICE, INBRED BALB C; VACCINATION; VIRION;

ESCHERICHIA COLI; ORTHOMYXOVIRIDAE;

EID: 66149125569     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02035-08     Document Type: Article

References (34)

1. Bagley, K. C., S. F. Abdelwahab, R. G. Tuskan, and G. K. Lewis. 2004. Calcium signaling through phospholipase C activates dendritic cells to mature and is necessary for the activation and maturation of dendritic cells induced by diverse agonists. Clin. Diagn. Lab. Immunol. 11:77-82. (Pubitemid 38090655)
2. Bright, R. A., D. M. Carter, C. J. Crevar, F. R. Toapanta, J. D. Steckbeck, K. S. Cole, N. M. Kumar, P. Pushko, G. Smith, T. M. Tumpey, and T. M. Ross. 2008. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3:e1501.
3. Bright, R. A., D. M. Carter, S. Daniluk, F. R. Toapanta, A. Ahmad, V. Gavrilov, M. Massare, P. Pushko, N. Mytle, T. Rowe, G. Smith, and T. M. Ross. 2007. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25:3871-3878.
4. Cuatrecasas, P. 1973. Gangliosides and membrane receptors for cholera toxin. Biochemistry 12:3558-3566.
5. Freytag, L. C., and J. D. Clements. 2005. Mucosal adjuvants. Vaccine 23:1804-1813.
6. Gagliardi, M. C., F. Sallusto, M. Marinaro, A. Langenkamp, A. Lanzavecchia, and M. T. De Magistris. 2000. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur. J. Immunol. 30:2394-2403. (Pubitemid 30655776)
7. Galarza, J. M., T. Latham, and A. Cupo. 2005. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 18:244-251. (Pubitemid 40586463)
8. Gillim-Ross, L., and K. Subbarao. 2006. Emerging respiratory viruses: challenges and vaccine strategies. Clin. Microbiol. Rev. 19:614-636.
9. Guarnaccia, S., S. M. Peters, F. Habib, G. R. Mancuso, S. P. Dibenedetto, M. Espey, and J. A. Bellanti. 1990. A comparative immunogenicity-reactogenicity dose-response study of influenza vaccine. Ann. Allergy 65:218-221. (Pubitemid 20295269)
10. Guebre-Xabier, M., S. A. Hammond, D. E. Epperson, J. Yu, L. Ellingsworth, and G. M. Glenn. 2003. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J. Virol. 77:5218-5225.
11. Hauge, S., A. S. Madhun, R. J. Cox, K. A. Brokstad, and L. R. Haaheim. 2007. A comparison of the humoral and cellular immune responses at different immunological sites after split influenza virus vaccination of mice. Scand. J. Immunol. 65:14-21.
12. Hovden, A. O., R. J. Cox, A. Madhun, and L. R. Haaheim. 2005. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scand. J. Immunol. 62:342-352. (Pubitemid 41565386)
13. James, J. M., R. S. Zeiger, M. R. Lester, M. B. Fasano, J. E. Gern, L. E. Mansfield, H. J. Schwartz, H. A. Sampson, H. H. Windom, S. B. Machtinger, and S. Lensing. 1998. Safe administration of influenza vaccine to patients with egg allergy. J. Pediatr. 133:624-628. (Pubitemid 28521210)
14. Jertborn, M., I. Nordstrom, A. Kilander, C. Czerkinsky, and J. Holmgren. 2001. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect. Immun. 69:4125-4128. (Pubitemid 32496267)
15. Luke, C. J., and K. Subbarao. 2006. Vaccines for pandemic influenza. Emerg. Infect. Dis. 12:66-72. (Pubitemid 43143538)
16. Lycke, N. 1997. The mechanism of cholera toxin adjuvanticity. Res. Immunol. 148:504-520. (Pubitemid 28179014)
17. Matassov, D., A. Cupo, and J. M. Galarza. 2007. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol. 20:441-452. (Pubitemid 47585318)
18. Mutsch, M., W. Zhou, P. Rhodes, M. Bopp, R. T. Chen, T. Linder, C. Spyr, and R. Steffen. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350:896-903. (Pubitemid 38252537)
19. Novak, M., Z. Moldoveanu, D. P. Schafer, J. Mestecky, and R. W. Compans. 1993. Murine model for evaluation of protective immunity to influenza virus. Vaccine 11:55-60.
20. Parkman, P. D., H. E. Hopps, S. C. Rastogi, and H. M. Meyer, Jr. 1977. Summary of clinical trials of influenza virus vaccines in adults. J. Infect. Dis. 136(Suppl.):S722-S730.
21. Peppoloni, S., P. Ruggiero, M. Contorni, M. Morandi, M. Pizza, R. Rappuoli, A. Podda, and G. Del Giudice. 2003. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines 2:285-293. (Pubitemid 36564799)
22. Pushko, P., T. M. Tumpey, F. Bu, J. Knell, R. Robinson, and G. Smith. 2005. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23:5751-5759.
23. Pushko, P., T. M. Tumpey, N. Van Hoeven, J. A. Belser, R. Robinson, M. Nathan, G. Smith, D. C. Wright, and R. A. Bright. 2007. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 25:4283-4290.
24. Quan, F. S., R. W. Compans, H. H. Nguyen, and S. M. Kang. 2008. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 82:1350-1359.
25. Quan, F. S., C. Huang, R. W. Compans, and S. M. Kang. 2007. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 81:3514-3524. (Pubitemid 46456660)
26. Quan, F. S., D. Steinhauer, C. Huang, T. M. Ross, R. W. Compans, and S. M. Kang. 2008. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 26:3352-3361.
27. + T-cell-independent immunoglobulin responses by inactivated influenza virus. J. Virol. 74:4999-5005.
28. Subbarao, K., B. R. Murphy, and A. S. Fauci. 2006. Development of effective vaccines against pandemic influenza. Immunity 24:5-9.
29. Suguitan, A. L., Jr., J. McAuliffe, K. L. Mills, H. Jin, G. Duke, B. Lu, C. J. Luke, B. Murphy, D. E. Swayne, G. Kemble, and K. Subbarao. 2006. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 3:e360.
30. Szyszko, E., K. Brokstad, R. J. Cox, A. O. Hovden, A. Madhun, and L. R. Haaheim. 2006. Impact of influenza vaccine formulation with a detailed analysis of the cytokine response. Scand. J. Immunol. 64:467-475. (Pubitemid 44536331)
31. Takada, A., S. Matsushita, A. Ninomiya, Y. Kawaoka, and H. Kida. 2003. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21:3212-3218.
32. Tamura, S., T. Tanimoto, and T. Kurata. 2005. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn. J. Infect. Dis. 58:195-207. (Pubitemid 41460922)
33. Tumpey, T. M., M. Renshaw, J. D. Clements, and J. M. Katz. 2001. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 75:5141-5150. (Pubitemid 32448536)
34. Wassén, L., K. Schon, J. Holmgren, M. Jertborn, and N. Lycke. 1996. Local intravaginal vaccination of the female genital tract. Scand. J. Immunol. 44:408-414. (Pubitemid 26327025)